Global Biosimilar Insulin Glargine Supply, Demand and Key Producers, 2024-2030
Page: 109
Published Date: 18 Feb 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Biosimilar Insulin Glargine market size is expected to reach $ 2533.8 million by 2030, rising at a market growth of 2.7% CAGR during the forecast period (2024-2030).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.
This report studies the global Biosimilar Insulin Glargine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Biosimilar Insulin Glargine, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Biosimilar Insulin Glargine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Biosimilar Insulin Glargine total production and demand, 2019-2030, (K Units)
Global Biosimilar Insulin Glargine total production value, 2019-2030, (USD Million)
Global Biosimilar Insulin Glargine production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Biosimilar Insulin Glargine consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Biosimilar Insulin Glargine domestic production, consumption, key domestic manufacturers and share
Global Biosimilar Insulin Glargine production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Biosimilar Insulin Glargine production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Biosimilar Insulin Glargine production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).
This reports profiles key players in the global Biosimilar Insulin Glargine market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Biosimilar Insulin Glargine market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Biosimilar Insulin Glargine Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Biosimilar Insulin Glargine Market, Segmentation by Type
Pre-filled
Cartridge
Global Biosimilar Insulin Glargine Market, Segmentation by Application
Hospital
Retail Pharmacy
Others
Companies Profiled:
Eli Lilly
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Key Questions Answered
1. How big is the global Biosimilar Insulin Glargine market?
2. What is the demand of the global Biosimilar Insulin Glargine market?
3. What is the year over year growth of the global Biosimilar Insulin Glargine market?
4. What is the production and production value of the global Biosimilar Insulin Glargine market?
5. Who are the key producers in the global Biosimilar Insulin Glargine market?
Table of Contents
1 Supply Summary
1.1 Biosimilar Insulin Glargine Introduction
1.2 World Biosimilar Insulin Glargine Supply & Forecast
1.2.1 World Biosimilar Insulin Glargine Production Value (2019 & 2023 & 2030)
1.2.2 World Biosimilar Insulin Glargine Production (2019-2030)
1.2.3 World Biosimilar Insulin Glargine Pricing Trends (2019-2030)
1.3 World Biosimilar Insulin Glargine Production by Region (Based on Production Site)
1.3.1 World Biosimilar Insulin Glargine Production Value by Region (2019-2030)
1.3.2 World Biosimilar Insulin Glargine Production by Region (2019-2030)
1.3.3 World Biosimilar Insulin Glargine Average Price by Region (2019-2030)
1.3.4 North America Biosimilar Insulin Glargine Production (2019-2030)
1.3.5 Europe Biosimilar Insulin Glargine Production (2019-2030)
1.3.6 China Biosimilar Insulin Glargine Production (2019-2030)
1.3.7 Japan Biosimilar Insulin Glargine Production (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Biosimilar Insulin Glargine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Biosimilar Insulin Glargine Major Market Trends
2.1 World Biosimilar Insulin Glargine Demand (2019-2030)
2.2 World Biosimilar Insulin Glargine Consumption by Region
2.2.1 World Biosimilar Insulin Glargine Consumption by Region (2019-2024)
2.2.2 World Biosimilar Insulin Glargine Consumption Forecast by Region (2025-2030)
2.3 United States Biosimilar Insulin Glargine Consumption (2019-2030)
2.4 China Biosimilar Insulin Glargine Consumption (2019-2030)
2.5 Europe Biosimilar Insulin Glargine Consumption (2019-2030)
2.6 Japan Biosimilar Insulin Glargine Consumption (2019-2030)
2.7 South Korea Biosimilar Insulin Glargine Consumption (2019-2030)
2.8 ASEAN Biosimilar Insulin Glargine Consumption (2019-2030)
2.9 India Biosimilar Insulin Glargine Consumption (2019-2030)
3.1 World Biosimilar Insulin Glargine Production Value by Manufacturer (2019-2024)
3.2 World Biosimilar Insulin Glargine Production by Manufacturer (2019-2024)
3.3 World Biosimilar Insulin Glargine Average Price by Manufacturer (2019-2024)
3.4 Biosimilar Insulin Glargine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Biosimilar Insulin Glargine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Biosimilar Insulin Glargine in 2023
3.5.3 Global Concentration Ratios (CR8) for Biosimilar Insulin Glargine in 2023
3.6 Biosimilar Insulin Glargine Market: Overall Company Footprint Analysis
3.6.1 Biosimilar Insulin Glargine Market: Region Footprint
3.6.2 Biosimilar Insulin Glargine Market: Company Product Type Footprint
3.6.3 Biosimilar Insulin Glargine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4.1 United States VS China: Biosimilar Insulin Glargine Production Value Comparison
4.1.1 United States VS China: Biosimilar Insulin Glargine Production Value Comparison (2019 & 2023 & 2030)
4.1.2 United States VS China: Biosimilar Insulin Glargine Production Value Market Share Comparison (2019 & 2023 & 2030)
4.2 United States VS China: Biosimilar Insulin Glargine Production Comparison
4.2.1 United States VS China: Biosimilar Insulin Glargine Production Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Biosimilar Insulin Glargine Production Market Share Comparison (2019 & 2023 & 2030)
4.3 United States VS China: Biosimilar Insulin Glargine Consumption Comparison
4.3.1 United States VS China: Biosimilar Insulin Glargine Consumption Comparison (2019 & 2023 & 2030)
4.3.2 United States VS China: Biosimilar Insulin Glargine Consumption Market Share Comparison (2019 & 2023 & 2030)
4.4 United States Based Biosimilar Insulin Glargine Manufacturers and Market Share, 2019-2024
4.4.1 United States Based Biosimilar Insulin Glargine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Biosimilar Insulin Glargine Production Value (2019-2024)
4.4.3 United States Based Manufacturers Biosimilar Insulin Glargine Production (2019-2024)
4.5 China Based Biosimilar Insulin Glargine Manufacturers and Market Share
4.5.1 China Based Biosimilar Insulin Glargine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Biosimilar Insulin Glargine Production Value (2019-2024)
4.5.3 China Based Manufacturers Biosimilar Insulin Glargine Production (2019-2024)
4.6 Rest of World Based Biosimilar Insulin Glargine Manufacturers and Market Share, 2019-2024
4.6.1 Rest of World Based Biosimilar Insulin Glargine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Biosimilar Insulin Glargine Production Value (2019-2024)
4.6.3 Rest of World Based Manufacturers Biosimilar Insulin Glargine Production (2019-2024)
5.1 World Biosimilar Insulin Glargine Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Pre-filled
5.2.2 Cartridge
5.3 Market Segment by Type
5.3.1 World Biosimilar Insulin Glargine Production by Type (2019-2030)
5.3.2 World Biosimilar Insulin Glargine Production Value by Type (2019-2030)
5.3.3 World Biosimilar Insulin Glargine Average Price by Type (2019-2030)
6.1 World Biosimilar Insulin Glargine Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Biosimilar Insulin Glargine Production by Application (2019-2030)
6.3.2 World Biosimilar Insulin Glargine Production Value by Application (2019-2030)
6.3.3 World Biosimilar Insulin Glargine Average Price by Application (2019-2030)
7.1 Eli Lilly
7.1.1 Eli Lilly Details
7.1.2 Eli Lilly Major Business
7.1.3 Eli Lilly Biosimilar Insulin Glargine Product and Services
7.1.4 Eli Lilly Biosimilar Insulin Glargine Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.1.5 Eli Lilly Recent Developments/Updates
7.1.6 Eli Lilly Competitive Strengths & Weaknesses
7.2 Gan&Lee
7.2.1 Gan&Lee Details
7.2.2 Gan&Lee Major Business
7.2.3 Gan&Lee Biosimilar Insulin Glargine Product and Services
7.2.4 Gan&Lee Biosimilar Insulin Glargine Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.2.5 Gan&Lee Recent Developments/Updates
7.2.6 Gan&Lee Competitive Strengths & Weaknesses
7.3 Tonghua Dongbao
7.3.1 Tonghua Dongbao Details
7.3.2 Tonghua Dongbao Major Business
7.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Product and Services
7.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.3.5 Tonghua Dongbao Recent Developments/Updates
7.3.6 Tonghua Dongbao Competitive Strengths & Weaknesses
7.4 United Laboratory
7.4.1 United Laboratory Details
7.4.2 United Laboratory Major Business
7.4.3 United Laboratory Biosimilar Insulin Glargine Product and Services
7.4.4 United Laboratory Biosimilar Insulin Glargine Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.4.5 United Laboratory Recent Developments/Updates
7.4.6 United Laboratory Competitive Strengths & Weaknesses
7.5 Geropharm
7.5.1 Geropharm Details
7.5.2 Geropharm Major Business
7.5.3 Geropharm Biosimilar Insulin Glargine Product and Services
7.5.4 Geropharm Biosimilar Insulin Glargine Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.5.5 Geropharm Recent Developments/Updates
7.5.6 Geropharm Competitive Strengths & Weaknesses
7.6 Biocon
7.6.1 Biocon Details
7.6.2 Biocon Major Business
7.6.3 Biocon Biosimilar Insulin Glargine Product and Services
7.6.4 Biocon Biosimilar Insulin Glargine Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.6.5 Biocon Recent Developments/Updates
7.6.6 Biocon Competitive Strengths & Weaknesses
7.7 Wockhardt
7.7.1 Wockhardt Details
7.7.2 Wockhardt Major Business
7.7.3 Wockhardt Biosimilar Insulin Glargine Product and Services
7.7.4 Wockhardt Biosimilar Insulin Glargine Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.7.5 Wockhardt Recent Developments/Updates
7.7.6 Wockhardt Competitive Strengths & Weaknesses
8.1 Biosimilar Insulin Glargine Industry Chain
8.2 Biosimilar Insulin Glargine Upstream Analysis
8.2.1 Biosimilar Insulin Glargine Core Raw Materials
8.2.2 Main Manufacturers of Biosimilar Insulin Glargine Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Biosimilar Insulin Glargine Production Mode
8.6 Biosimilar Insulin Glargine Procurement Model
8.7 Biosimilar Insulin Glargine Industry Sales Model and Sales Channels
8.7.1 Biosimilar Insulin Glargine Sales Model
8.7.2 Biosimilar Insulin Glargine Typical Customers
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Biosimilar Insulin Glargine Production Value by Region (2019, 2023 and 2030) & (USD Million)
Table 2. World Biosimilar Insulin Glargine Production Value by Region (2019-2024) & (USD Million)
Table 3. World Biosimilar Insulin Glargine Production Value by Region (2025-2030) & (USD Million)
Table 4. World Biosimilar Insulin Glargine Production Value Market Share by Region (2019-2024)
Table 5. World Biosimilar Insulin Glargine Production Value Market Share by Region (2025-2030)
Table 6. World Biosimilar Insulin Glargine Production by Region (2019-2024) & (K Units)
Table 7. World Biosimilar Insulin Glargine Production by Region (2025-2030) & (K Units)
Table 8. World Biosimilar Insulin Glargine Production Market Share by Region (2019-2024)
Table 9. World Biosimilar Insulin Glargine Production Market Share by Region (2025-2030)
Table 10. World Biosimilar Insulin Glargine Average Price by Region (2019-2024) & (US$/Unit)
Table 11. World Biosimilar Insulin Glargine Average Price by Region (2025-2030) & (US$/Unit)
Table 12. Biosimilar Insulin Glargine Major Market Trends
Table 13. World Biosimilar Insulin Glargine Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
Table 14. World Biosimilar Insulin Glargine Consumption by Region (2019-2024) & (K Units)
Table 15. World Biosimilar Insulin Glargine Consumption Forecast by Region (2025-2030) & (K Units)
Table 16. World Biosimilar Insulin Glargine Production Value by Manufacturer (2019-2024) & (USD Million)
Table 17. Production Value Market Share of Key Biosimilar Insulin Glargine Producers in 2023
Table 18. World Biosimilar Insulin Glargine Production by Manufacturer (2019-2024) & (K Units)
Table 19. Production Market Share of Key Biosimilar Insulin Glargine Producers in 2023
Table 20. World Biosimilar Insulin Glargine Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 21. Global Biosimilar Insulin Glargine Company Evaluation Quadrant
Table 22. World Biosimilar Insulin Glargine Industry Rank of Major Manufacturers, Based on Production Value in 2023
Table 23. Head Office and Biosimilar Insulin Glargine Production Site of Key Manufacturer
Table 24. Biosimilar Insulin Glargine Market: Company Product Type Footprint
Table 25. Biosimilar Insulin Glargine Market: Company Product Application Footprint
Table 26. Biosimilar Insulin Glargine Competitive Factors
Table 27. Biosimilar Insulin Glargine New Entrant and Capacity Expansion Plans
Table 28. Biosimilar Insulin Glargine Mergers & Acquisitions Activity
Table 29. United States VS China Biosimilar Insulin Glargine Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 30. United States VS China Biosimilar Insulin Glargine Production Comparison, (2019 & 2023 & 2030) & (K Units)
Table 31. United States VS China Biosimilar Insulin Glargine Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
Table 32. United States Based Biosimilar Insulin Glargine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Biosimilar Insulin Glargine Production Value, (2019-2024) & (USD Million)
Table 34. United States Based Manufacturers Biosimilar Insulin Glargine Production Value Market Share (2019-2024)
Table 35. United States Based Manufacturers Biosimilar Insulin Glargine Production (2019-2024) & (K Units)
Table 36. United States Based Manufacturers Biosimilar Insulin Glargine Production Market Share (2019-2024)
Table 37. China Based Biosimilar Insulin Glargine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Biosimilar Insulin Glargine Production Value, (2019-2024) & (USD Million)
Table 39. China Based Manufacturers Biosimilar Insulin Glargine Production Value Market Share (2019-2024)
Table 40. China Based Manufacturers Biosimilar Insulin Glargine Production (2019-2024) & (K Units)
Table 41. China Based Manufacturers Biosimilar Insulin Glargine Production Market Share (2019-2024)
Table 42. Rest of World Based Biosimilar Insulin Glargine Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Biosimilar Insulin Glargine Production Value, (2019-2024) & (USD Million)
Table 44. Rest of World Based Manufacturers Biosimilar Insulin Glargine Production Value Market Share (2019-2024)
Table 45. Rest of World Based Manufacturers Biosimilar Insulin Glargine Production (2019-2024) & (K Units)
Table 46. Rest of World Based Manufacturers Biosimilar Insulin Glargine Production Market Share (2019-2024)
Table 47. World Biosimilar Insulin Glargine Production Value by Type, (USD Million), 2019 & 2023 & 2030
Table 48. World Biosimilar Insulin Glargine Production by Type (2019-2024) & (K Units)
Table 49. World Biosimilar Insulin Glargine Production by Type (2025-2030) & (K Units)
Table 50. World Biosimilar Insulin Glargine Production Value by Type (2019-2024) & (USD Million)
Table 51. World Biosimilar Insulin Glargine Production Value by Type (2025-2030) & (USD Million)
Table 52. World Biosimilar Insulin Glargine Average Price by Type (2019-2024) & (US$/Unit)
Table 53. World Biosimilar Insulin Glargine Average Price by Type (2025-2030) & (US$/Unit)
Table 54. World Biosimilar Insulin Glargine Production Value by Application, (USD Million), 2019 & 2023 & 2030
Table 55. World Biosimilar Insulin Glargine Production by Application (2019-2024) & (K Units)
Table 56. World Biosimilar Insulin Glargine Production by Application (2025-2030) & (K Units)
Table 57. World Biosimilar Insulin Glargine Production Value by Application (2019-2024) & (USD Million)
Table 58. World Biosimilar Insulin Glargine Production Value by Application (2025-2030) & (USD Million)
Table 59. World Biosimilar Insulin Glargine Average Price by Application (2019-2024) & (US$/Unit)
Table 60. World Biosimilar Insulin Glargine Average Price by Application (2025-2030) & (US$/Unit)
Table 61. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 62. Eli Lilly Major Business
Table 63. Eli Lilly Biosimilar Insulin Glargine Product and Services
Table 64. Eli Lilly Biosimilar Insulin Glargine Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 65. Eli Lilly Recent Developments/Updates
Table 66. Eli Lilly Competitive Strengths & Weaknesses
Table 67. Gan&Lee Basic Information, Manufacturing Base and Competitors
Table 68. Gan&Lee Major Business
Table 69. Gan&Lee Biosimilar Insulin Glargine Product and Services
Table 70. Gan&Lee Biosimilar Insulin Glargine Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 71. Gan&Lee Recent Developments/Updates
Table 72. Gan&Lee Competitive Strengths & Weaknesses
Table 73. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 74. Tonghua Dongbao Major Business
Table 75. Tonghua Dongbao Biosimilar Insulin Glargine Product and Services
Table 76. Tonghua Dongbao Biosimilar Insulin Glargine Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Tonghua Dongbao Recent Developments/Updates
Table 78. Tonghua Dongbao Competitive Strengths & Weaknesses
Table 79. United Laboratory Basic Information, Manufacturing Base and Competitors
Table 80. United Laboratory Major Business
Table 81. United Laboratory Biosimilar Insulin Glargine Product and Services
Table 82. United Laboratory Biosimilar Insulin Glargine Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 83. United Laboratory Recent Developments/Updates
Table 84. United Laboratory Competitive Strengths & Weaknesses
Table 85. Geropharm Basic Information, Manufacturing Base and Competitors
Table 86. Geropharm Major Business
Table 87. Geropharm Biosimilar Insulin Glargine Product and Services
Table 88. Geropharm Biosimilar Insulin Glargine Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Geropharm Recent Developments/Updates
Table 90. Geropharm Competitive Strengths & Weaknesses
Table 91. Biocon Basic Information, Manufacturing Base and Competitors
Table 92. Biocon Major Business
Table 93. Biocon Biosimilar Insulin Glargine Product and Services
Table 94. Biocon Biosimilar Insulin Glargine Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 95. Biocon Recent Developments/Updates
Table 96. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 97. Wockhardt Major Business
Table 98. Wockhardt Biosimilar Insulin Glargine Product and Services
Table 99. Wockhardt Biosimilar Insulin Glargine Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 100. Global Key Players of Biosimilar Insulin Glargine Upstream (Raw Materials)
Table 101. Biosimilar Insulin Glargine Typical Customers
Table 102. Biosimilar Insulin Glargine Typical Distributors
List of Figure
Figure 1. Biosimilar Insulin Glargine Picture
Figure 2. World Biosimilar Insulin Glargine Production Value: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Biosimilar Insulin Glargine Production Value and Forecast (2019-2030) & (USD Million)
Figure 4. World Biosimilar Insulin Glargine Production (2019-2030) & (K Units)
Figure 5. World Biosimilar Insulin Glargine Average Price (2019-2030) & (US$/Unit)
Figure 6. World Biosimilar Insulin Glargine Production Value Market Share by Region (2019-2030)
Figure 7. World Biosimilar Insulin Glargine Production Market Share by Region (2019-2030)
Figure 8. North America Biosimilar Insulin Glargine Production (2019-2030) & (K Units)
Figure 9. Europe Biosimilar Insulin Glargine Production (2019-2030) & (K Units)
Figure 10. China Biosimilar Insulin Glargine Production (2019-2030) & (K Units)
Figure 11. Japan Biosimilar Insulin Glargine Production (2019-2030) & (K Units)
Figure 12. Biosimilar Insulin Glargine Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 15. World Biosimilar Insulin Glargine Consumption Market Share by Region (2019-2030)
Figure 16. United States Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 17. China Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 18. Europe Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 19. Japan Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 20. South Korea Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 21. ASEAN Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 22. India Biosimilar Insulin Glargine Consumption (2019-2030) & (K Units)
Figure 23. Producer Shipments of Biosimilar Insulin Glargine by Manufacturer Revenue ($MM) and Market Share (%): 2023
Figure 24. Global Four-firm Concentration Ratios (CR4) for Biosimilar Insulin Glargine Markets in 2023
Figure 25. Global Four-firm Concentration Ratios (CR8) for Biosimilar Insulin Glargine Markets in 2023
Figure 26. United States VS China: Biosimilar Insulin Glargine Production Value Market Share Comparison (2019 & 2023 & 2030)
Figure 27. United States VS China: Biosimilar Insulin Glargine Production Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Biosimilar Insulin Glargine Consumption Market Share Comparison (2019 & 2023 & 2030)
Figure 29. United States Based Manufacturers Biosimilar Insulin Glargine Production Market Share 2023
Figure 30. China Based Manufacturers Biosimilar Insulin Glargine Production Market Share 2023
Figure 31. Rest of World Based Manufacturers Biosimilar Insulin Glargine Production Market Share 2023
Figure 32. World Biosimilar Insulin Glargine Production Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 33. World Biosimilar Insulin Glargine Production Value Market Share by Type in 2023
Figure 34. Pre-filled
Figure 35. Cartridge
Figure 36. World Biosimilar Insulin Glargine Production Market Share by Type (2019-2030)
Figure 37. World Biosimilar Insulin Glargine Production Value Market Share by Type (2019-2030)
Figure 38. World Biosimilar Insulin Glargine Average Price by Type (2019-2030) & (US$/Unit)
Figure 39. World Biosimilar Insulin Glargine Production Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 40. World Biosimilar Insulin Glargine Production Value Market Share by Application in 2023
Figure 41. Hospital
Figure 42. Retail Pharmacy
Figure 43. Others
Figure 44. World Biosimilar Insulin Glargine Production Market Share by Application (2019-2030)
Figure 45. World Biosimilar Insulin Glargine Production Value Market Share by Application (2019-2030)
Figure 46. World Biosimilar Insulin Glargine Average Price by Application (2019-2030) & (US$/Unit)
Figure 47. Biosimilar Insulin Glargine Industry Chain
Figure 48. Biosimilar Insulin Glargine Procurement Model
Figure 49. Biosimilar Insulin Glargine Sales Model
Figure 50. Biosimilar Insulin Glargine Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Eli Lilly Gan&Lee Tonghua Dongbao United Laboratory Geropharm Biocon Wockhardt
Related Reports
09 Jan 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
